Table 2. Comparison of patient characteristics according to FOXA1 H-score.
| Variable | FOXA1 H-Score 0–3 (N = 77) | FOXA1 H-Score 4–8 (N = 64) | P-value |
|---|---|---|---|
| Pre-RP PSA (ng/mL) | 8.8 (1.6, 219.0) | 10.5 (2.0, 155.0) | 0.25 |
| Pre-SRT PSA (ng/mL) | 0.6 (0.1, 4.9) | 0.5 (0.1, 15.3) | 0.14 |
| SRT dose (Gy) | 64.8 (58.4, 70.2) | 65.0 (59.4, 72.4) | 0.27 |
| Age | 67.0 (46.1, 81.1) | 66.2 (44.0, 80.7) | 0.49 |
| Length of time from RP to SRT initiation (months) | 15.5 (3.0, 71.9) | 11.7 (1.5, 99.3) | 0.061 |
| Pathological tumor stage | 0.45 | ||
| T2 | 14 (18.2%) | 7 (10.9%) | |
| T3a | 40 (51.9%) | 39 (60.9%) | |
| T3b | 23 (29.9%) | 18 (28.1%) | |
| Surgical margin | 0.61 | ||
| Positive | 44 (57.1%) | 40 (62.5%) | |
| Negative | 33 (42.9%) | 24 (37.5%) | |
| Gleason score | 0.48 | ||
| 3–6 | 27 (35.1%) | 28 (45.2%) | |
| 7 | 32 (41.6%) | 23 (37.1%) | |
| 8–10 | 18 (23.4%) | 11 (17.7%) | |
| Pre-SRT hormone therapy | 0.66 | ||
| Yes | 13 (16.9%) | 13 (20.3%) | |
| No | 67 (83.1%) | 51 (79.7%) | |
| Staining batch | 0.001 | ||
| First | 30 (39.0%) | 43 (67.2%) | |
| Second | 47 (61.0%) | 21 (32.8%) |
The sample median (minimum, maximum) is given for continuous variables. P-values result from a Kruskal-Wallis rank sum test (continuous variables) or Fisher’s exact test (categorical variables). Information was unavailable regarding pre-RP PSA (N = 5) and Gleason score (N = 2). RP = radical prostatectomy; PSA = prostate-specific antigen; SRT = salvage radiation therapy.